{"id":"lutetium-177lu-oxodotreotide","rwe":[{"pmid":"41739362","year":"2026","title":"Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.","finding":"","journal":"EJNMMI research","studyType":"Clinical Study"},{"pmid":"39607652","year":"2024","title":"Radiation exposure and protection advice after [(177)Lu]Lu-DOTA-TATE therapy in China.","finding":"","journal":"EJNMMI research","studyType":"Clinical Study"},{"pmid":"37987917","year":"2024","title":"Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group.","finding":"","journal":"Advances in therapy","studyType":"Clinical Study"}],"_fda":{"id":"74d44dec-f079-43b7-94ac-989a948f53ec","set_id":"72d1a024-00b7-418a-b36e-b2cb48f2ab55","openfda":{"unii":["AE221IM3BB"],"route":["INTRAVENOUS"],"rxcui":["1999682","1999687"],"spl_id":["74d44dec-f079-43b7-94ac-989a948f53ec"],"brand_name":["Lutathera"],"spl_set_id":["72d1a024-00b7-418a-b36e-b2cb48f2ab55"],"package_ndc":["69488-003-01"],"product_ndc":["69488-003"],"generic_name":["LUTETIUM LU 177 DOTATATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["LUTETIUM OXODOTREOTIDE LU-177"],"manufacturer_name":["Advanced Accelerator Applications USA, Inc"],"application_number":["NDA208700"],"is_original_packager":[true]},"version":"12","pregnancy":["8.1 Pregnancy Risk Summary Based on its mechanism of action, LUTATHERA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data on LUTATHERA use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from LUTATHERA, can cause fetal harm. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."],"description":["11 DESCRIPTION Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog. The drug substance lutetium Lu 177 dotatate is a cyclic peptide linked with the covalently bound chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid to a radionuclide. Lutetium Lu 177 dotatate is described as lutetium (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl) acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic (2-7) disulfide. The molecular weight is 1609.6 Daltons and the structural formula is as follows: LUTATHERA (lutetium Lu 177 dotatate) 370 MBq/mL (10 mCi/mL) Injection is a sterile, clear, colorless to slightly yellow solution for intravenous use. Each single-dose vial contains acetic acid (0.48 mg/mL), sodium acetate (0.66 mg/mL), gentisic acid (0.63 mg/mL), sodium hydroxide (0.64 mg/mL), ascorbic acid (2.8 mg/mL), diethylene triamine pentaacetic acid (0.05 mg/mL), sodium chloride (6.85 mg/mL), and Water for Injection (ad 1 mL). The pH range of the solution is 4.5 to 6. Lutetium Lu 177 dotatate structural formula 11.1 Physical Characteristics Lutetium-177 decays to stable hafnium-177 with a half-life of 6.647 days, by emitting beta-minus radiation with a maximum energy of 0.498 MeV (79%) and photonic radiation (γ) of 0.208 MeV (11%) and 0.113 MeV (6.2%). The main radiations of lutetium-177 are detailed in Table 7. Table 7. Lutetium-177 Main Radiations Radiation Energy (keV) Iβ - % Iγ% β - 176.5 12.2 β - 248.1 0.05 β - 384.9 9.1 β - 497.8 78.6 γ 71.6 0.15 γ 112.9 6.20 γ 136.7 0.05 γ 208.4 11.0 γ 249.7 0.21 γ 321.3 0.22 11.2 External Radiation Table 8 summarizes the radioactive decay properties of lutetium-177. Table 8. Physical Decay Chart: Lutetium-177 Physical Half-Life = 6.647 Days Hours Fraction remaining Hours Fraction remaining 0 1.000 48 (2 days) 0.812 1 0.996 72 (3 days) 0.731 2 0.991 168 (7 days) 0.482 5 0.979 336 (14 days) 0.232 10 0.958 720 (30 days) 0.044 24 (1 day) 0.901 1080 (45 days) 0.009"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING LUTATHERA Injection containing 370 MBq/mL (10 mCi/mL) of lutetium Lu 177 dotatate is a sterile, preservative-free and clear, colorless to slightly yellow solution for intravenous use supplied in a clear, colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 dotatate at the time of injection (NDC# 69488-003-01). The solution volume in the vial ranges between 20.5 to 25 mL to provide a total of 7.4 GBq (200 mCi) of radioactivity. The product vial is enclosed within a lead shielded container (NDC# 69488-003-01) placed in a plastic sealed container. The product is shipped in a Type A package. Store below 25°C (77°F). Do not freeze LUTATHERA. Store in the original package to protect from ionizing radiation (lead shielding). The shelf life is 72 hours from the date and time of calibration. Discard appropriately at 72 hours. Lutetium-177 for LUTATHERA may be prepared using two different sources of stable nuclides (either lutetium-176 or ytterbium-176) resulting in different waste management. Consult the documentation provided before using LUTATHERA to ensure appropriate waste management."],"geriatric_use":["8.5 Geriatric Use Of the 1325 patients treated with LUTATHERA in clinical trials, 438 patients (33%) were 65 years and older. No overall differences in safety or effectiveness were observed between older and younger patients."],"pediatric_use":["8.4 Pediatric Use Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors The safety and effectiveness of LUTATHERA have been established in pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Use of LUTATHERA for this indication is supported by evidence from an adequate and well-controlled study of LUTATHERA in adults with additional safety, pharmacokinetic, and dosimetry data in pediatric patients aged 12 years and older with somatostatin receptor-positive tumors, including 4 pediatric patients with GEP-NETs [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), Clinical Studies ( 14 )] . The risks of radiation exposure associated with LUTATHERA are greater in pediatric patients than in adult patients due to longer life expectancy. Continued follow-up is recommended for evaluation of long-term effects. There was no clinically relevant difference in lutetium Lu 177 dotatate exposure in pediatric patients aged 13 to 16 years versus adult patients [see Clinical Pharmacology ( 12.3 )] . The pharmacokinetic profile and safety of LUTATHERA in pediatric patients 12 years and older with baseline renal impairment have not been studied. The safety and effectiveness of LUTATHERA have not been established in pediatric patients younger than 12 years old with somatostatin receptor-positive GEP-NETs."],"effective_time":"20260115","clinical_studies":["14 CLINICAL STUDIES 14.1 Progressive, Well-Differentiated Advanced or Metastatic Somatostatin Receptor-Positive Midgut Carcinoid Tumors The efficacy of LUTATHERA in patients with progressive, well-differentiated, locally advanced/inoperable or metastatic somatostatin receptor-positive midgut carcinoid tumors was established in NETTER-1 (NCT01578239), a randomized, multicenter, open-label, active-controlled trial. Key eligibility criteria included Ki67 index ≤ 20%, Karnofsky performance status ≥ 60, confirmed presence of somatostatin receptors on all lesions (OctreoScan uptake ≥ normal liver), creatinine clearance ≥ 50 mL/min, no prior treatment with peptide receptor radionuclide therapy (PRRT), and no prior external beam radiation therapy to more than 25% of the bone marrow. At the time of the primary analysis, 229 patients were randomized (1:1) to receive either LUTATHERA 7.4 GBq (200 mCi) every 8 weeks (±1 week) for up to 4 administrations (maximum cumulative dose of 29.6 GBq) or high-dose long-acting octreotide (defined as 60 mg by intramuscular injection every 4 weeks). Patients in the LUTATHERA arm also received long-acting octreotide 30 mg as an intramuscular injection 4 to 24 hours after each LUTATHERA dose and every 4 weeks after completion of LUTATHERA treatment until disease progression or until week 76 of the study. Patients in both arms could receive short-acting octreotide for symptom management; however, short-acting octreotide was withheld at least 24 hours before each LUTATHERA dose. Randomization was stratified by OctreoScan tumor uptake score (Grade 2, 3, or 4) and the length of time that patients had been on the most recent constant dose of octreotide prior to randomization (≤ 6 or > 6 months). The major efficacy outcome measure was progression-free survival (PFS) as determined by a blinded independent review committee (IRC) per RECIST v1.1. Additional efficacy outcome measures were overall response rate (ORR) by IRC, duration of response (DoR) by IRC, and overall survival (OS). Demographic and baseline disease characteristics were balanced between the treatment arms. Of the 229 patients, 82% were White, 4% were Black, 3% were Hispanic or Latino, 0.4% were Asian, 0.4% were Other, and 9% were not reported. The median age was 64 years (28 to 87 years); 51% were male, 74% had an ileal primary, and 96% had metastatic disease in the liver. The median Karnofsky performance score was 90 (60 to 100), 74% received a constant dose of octreotide for > 6 months and 12% received prior treatment with everolimus. Sixty-nine percent of patients had Ki67 expression in ≤ 2% of tumor cells, 77% had CgA > 2 times the upper limit of normal (ULN), 65% had 5-HIAA > 2 times ULN, and 65% had alkaline phosphatase ≤ ULN. At the time of the final OS analysis, which occurred 66 months after the primary PFS analysis, 117 patients were randomized to the LUTATHERA arm and 114 patients were randomized to the octreotide arm. In the final OS analysis, there was no statistically significant difference in OS between the two treatment arms. Efficacy results for NETTER-1 are presented in Table 9 and Figure 1. Table 9. Efficacy Results in NETTER-1 Abbreviations: CI, confidence interval; IRC, independent radiology committee; NE, not evaluable; NR, not reached; ORR, overall response rate; PFS, progression-free survival. a Hazard ratio based on the unstratified Cox model. b Unstratified log rank test. c Fisher’s exact test. LUTATHERA with long-acting Octreotide (30 mg) N = 116 Long-acting Octreotide (60 mg) N = 113 PFS by IRC Events (%) 27 (23%) 78 (69%) Progressive disease, n (%) 15 (13%) 61 (54%) Death, n (%) 12 (10%) 17 (15%) Median in months (95% CI) NR (18.4, NE) 8.5 (6.0, 9.1) Hazard ratio a (95% CI) 0.21 (0.13, 0.32) p-value b < 0.0001 ORR by IRC ORR, % (95% CI) 13% (7%, 19%) 4% (0.1%, 7%) Complete response rate, n (%) 1 (1%) 0 Partial response rate, n (%) 14 (12%) 4 (4%) p-value c 0.0148 Duration of response, median in months (95% CI) NR (2.8, NE) 1.9 (1.9, NE) Figure 1. Kaplan-Meier Curves for Progression-Free Survival in NETTER-1 Figure 1. Kaplan-Meier Curves for Progression-Free Survival in NETTER-1 14.2 Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors The efficacy of LUTATHERA in patients with foregut, midgut, and hindgut gastroenteropancreatic neuroendocrine tumors (GEP-NETs) was assessed in 360 patients in the ERASMUS study. In ERASMUS, LUTATHERA was initially provided as expanded access under a general peptide receptor radionuclide therapy protocol at a single site in the Netherlands. A subsequent LUTATHERA-specific protocol written eight years after study initiation did not describe a specific sample size or hypothesis testing plan but allowed for retrospective data collection. A total of 1214 patients received LUTATHERA in ERASMUS, of whom 578 patients had baseline tumor assessments. Of the 578 patients, 360 (62%) had GEP-NETs and long-term follow-up. Of these 360 patients, 145 (40%) had their tumors prospectively evaluated according to RECIST criteria. LUTATHERA 7.4 GBq (200 mCi) was administered every 6 to 13 weeks for up to 4 doses concurrently with the recommended amino acid solution. The major efficacy outcome was investigator-assessed ORR. The median age in the efficacy subset was 60 years (30 to 85 years), 51% were male, 71% had a baseline Karnofsky performance status ≥ 90, 51% had progressed within 12 months of treatment, and 7% had received prior chemotherapy. Fifty-two percent (52%) of patients received a concomitant somatostatin analog. The median dose of LUTATHERA was 29.6 GBq (800 mCi). The investigator-assessed ORR was 17% (95% CI: 13, 21) based on an analysis that required responders to have had prospective response assessments according to RECIST criteria. Three complete responses were observed (< 1%). Median DoR in the 60 responding patients was 35 months (95% CI: 17, 38)."],"pharmacodynamics":["12.2 Pharmacodynamics Lutetium Lu 177 dotatate exposure-response relationships and the time course of pharmacodynamics response are unknown. Cardiac Electrophysiology The ability of LUTATHERA to prolong the QTc interval at the recommended dose was assessed in an open-label study in 20 patients with somatostatin receptor-positive midgut carcinoid tumors. No large changes in the mean QTc interval (i.e., > 20 ms) were detected."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics (PK) of lutetium Lu 177 dotatate have been characterized in patients with progressive, somatostatin receptor-positive neuroendocrine tumors. The mean blood exposure (area under the curve) of lutetium Lu 177 dotatate at the recommended dose is 41 ng.h/mL [coefficient of variation (CV) 36%]. The mean maximum blood concentration (C max ) for lutetium Lu 177 dotatate is 10 ng/mL (CV 50%), which generally occurred at the end of the LUTATHERA infusion. Distribution The mean volume of distribution (V z ) for lutetium Lu 177 dotatate is 460 L (CV 54%). The non-radioactive lutetium Lu 175 dotatate is 43% bound to human plasma proteins. Within 4 hours after administration, lutetium Lu 177 dotatate distributes in kidneys, tumor lesions, liver, spleen, and, in some patients, pituitary gland and thyroid. The co-administration of amino acids reduced the median radiation dose to the kidneys by 47% (34% to 59%) and increased the mean beta-phase blood clearance of lutetium Lu 177 dotatate by 36%. Elimination The mean clearance (CL) is 4.5 L/h (CV 31%) and the mean terminal half-life is 71 (±28) hours for lutetium 177 dotatate. Metabolism Lutetium Lu 177 dotatate does not undergo hepatic metabolism. Excretion Lutetium Lu 177 dotatate is primarily eliminated renally with cumulative excretion of 44% within 5 hours, 58% within 24 hours, and 65% within 48 hours following LUTATHERA administration. Prolonged elimination of lutetium Lu 177 dotatate in the urine is expected; however, based on the half-life of lutetium-177 and terminal half-life of lutetium Lu 177 dotatate, greater than 99% of the administered radioactivity will be eliminated within 14 days after administration of LUTATHERA [see Warnings and Precautions ( 5.1 )] . Special Populations Pediatric Patients There were no clinically relevant differences in exposure of lutetium Lu 177 dotatate in pediatric patients 12 years and older compared to that of adult patients. Drug Interaction Studies In Vitro Studies CYP450 enzymes: The non-radioactive lutetium Lu 175 dotatate is not an inhibitor or inducer of cytochrome P450 (CYP) 1A2, 2B6, 2C9, 2C19 or 2D6 in vitro. Transporters: The non-radioactive lutetium Lu 175 dotatate is not an inhibitor of P-glycoprotein, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, or OATP1B3 in vitro."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions ( 5.2 )] Secondary Myelodysplastic Syndrome and Leukemia [see Warnings and Precautions ( 5.3 )] Renal Toxicity [see Warnings and Precautions ( 5.4 )] Hepatotoxicity [see Warnings and Precautions ( 5.5 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.6 )] Neuroendocrine Hormonal Crisis [see Warnings and Precautions ( 5.7 )] Most common Grade 3-4 adverse reactions (≥ 4% with a higher incidence in LUTATHERA arm) are lymphopenia, increased GGT, vomiting, nausea, increased AST, increased ALT, hyperglycemia and hypokalemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in WARNINGS AND PRECAUTIONS reflect exposure to LUTATHERA in 111 patients with advanced, progressive midgut neuroendocrine tumors (NETTER-1). Safety data in WARNINGS AND PRECAUTIONS were also obtained in an additional 22 patients in a non-randomized pharmacokinetic sub-study of NETTER-1 and in a subset of patients (811 of 1214) with advanced somatostatin receptor-positive tumors enrolled in ERASMUS [see Warnings and Precautions ( 5 )] . Adult Population NETTER-1 The safety data of LUTATHERA with octreotide was evaluated in NETTER-1 [see Clinical Studies ( 14.1 )] . Patients with progressive, somatostatin receptor-positive midgut carcinoid tumors received LUTATHERA 7.4 GBq (200 mCi) administered every 8 to 16 weeks concurrently with the recommended amino acid solution and with long-acting octreotide (30 mg administered by intramuscular injection within 24 hours of each LUTATHERA dose) (N = 111), or high-dose octreotide (defined as long-acting octreotide 60 mg by intramuscular injection every 4 weeks) (N = 112) [see Clinical Studies ( 14.1 )] . Among patients receiving LUTATHERA with octreotide, 79% received a cumulative dose > 22.2 GBq (> 600 mCi) and 76% of patients received all four planned doses. Six percent (6%) of patients required a dose reduction and 13% of patients discontinued LUTATHERA. Five patients discontinued LUTATHERA for renal-related events and 4 discontinued for hematological toxicities. Table 5 and Table 6 summarize the incidence of adverse reactions and laboratory abnormalities, respectively. The most common Grade 3-4 adverse reactions occurring with a greater frequency among patients receiving LUTATHERA with octreotide compared to patients receiving high-dose octreotide include: lymphopenia (44%), increased gamma-glutamyltransferase (GGT) (20%), vomiting (7%), nausea and increased aspartate aminotransferase (AST) (5% each), and increased alanine aminotransferase (ALT), hyperglycemia and hypokalemia (4% each). Table 5. Adverse Reactions Occurring at Higher Incidence in Patients Receiving LUTATHERA with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3-4) a a National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays adverse reactions occurring at a higher incidence in LUTATHERA-treated patients [between arm difference of ≥ 5% (all Grades) or ≥ 2% (Grades 3-4)]. b Includes the terms: Glomerular filtration rate decreased, acute kidney injury, acute prerenal failure, azotemia, renal disorder, renal failure, renal impairment. c Includes the terms: Dysuria, micturition urgency, nocturia, pollakiuria, renal colic, renal pain, urinary tract pain and urinary incontinence. Adverse reaction a LUTATHERA with long-acting Octreotide (30 mg) (N = 111) Long-acting Octreotide (60 mg) (N = 112) All Grades % Grades 3-4 % All Grades % Grades 3-4 % Gastrointestinal disorders Nausea 65 5 12 2 Vomiting 53 7 10 0 Abdominal pain 26 3 19 3 Diarrhea 26 3 18 1 Constipation 10 0 5 0 General disorders Fatigue 38 1 26 2 Peripheral edema 16 0 9 1 Pyrexia 8 0 3 0 Metabolism and nutrition disorders Decreased appetite 21 0 11 3 Nervous system disorders Headache 17 0 5 0 Dizziness 17 0 8 0 Dysgeusia 8 0 2 0 Vascular disorders Flushing 14 1 9 0 Hypertension 12 2 7 2 Musculoskeletal and connective tissue disorders Back pain 13 2 10 0 Pain in extremity 11 0 5 0 Myalgia 5 0 0 0 Neck pain 5 0 0 0 Renal and urinary disorders Renal failure b 13 3 4 1 Radiation-related urinary tract adverse reactions c 8 0 3 0 Psychiatric disorders Anxiety 12 1 5 0 Skin and subcutaneous tissue disorders Alopecia 12 0 2 0 Respiratory, thoracic and mediastinal disorders Cough 11 1 6 0 Cardiac disorders Atrial fibrillation 5 1 0 0 Table 6. Laboratory Abnormalities Occurring at Higher Incidence in Patients Receiving LUTATHERA with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3-4) a,b a Values are worst grade observed after randomization. b National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays laboratory abnormalities occurring at a higher incidence in LUTATHERA-treated patients [between arm difference of ≥ 5% (all Grades) or ≥ 2% (Grades 3-4)]. Laboratory abnormality b LUTATHERA with long-acting Octreotide (30 mg) (N = 111) Long-acting Octreotide (60 mg) (N = 112) All Grades % Grades 3-4 % All Grades % Grades 3-4 % Hematology Lymphopenia 90 44 39 5 Anemia 81 0 55 1 Leukopenia 55 2 20 0 Thrombocytopenia 53 1 17 0 Neutropenia 26 3 11 0 Renal/Metabolic Creatinine increased 85 1 73 0 Hyperglycemia 82 4 67 2 Hyperuricemia 34 6 30 6 Hypocalcemia 32 0 14 0 Hypokalemia 26 4 21 2 Hyperkalemia 19 0 11 0 Hypernatremia 17 0 7 0 Hypoglycemia 15 0 8 0 Hepatic GGT increased 66 20 67 16 Alkaline phosphatase increased 65 5 55 9 AST increased 50 5 35 0 ALT increased 43 4 34 0 Blood bilirubin increased 30 2 28 0 ERASMUS Safety data are available from 1214 patients in ERASMUS, an international, single-institution, single-arm, open-label trial of patients with somatostatin receptor-positive tumors (neuroendocrine and other primaries). Patients received LUTATHERA 7.4 GBq (200 mCi) administered every 6 to 13 weeks with or without octreotide. Retrospective medical record review was conducted on a subset of 811 patients to document serious adverse reactions. Eighty-one (81%) percent of patients in the subset received a cumulative dose ≥ 22.2 GBq (≥ 600 mCi). With a median follow-up time of more than 4 years, the following rates of serious adverse reactions were reported: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal crisis (1%). Pediatric Population NETTER-P Safety data are available from 9 pediatric patients in NETTER-P (NCT04711135), an international, multi-center, single-arm, open-label trial of patients with somatostatin receptor-positive tumors, including 4 patients with GEP-NETs. Patients received LUTATHERA 7.4 GBq (200 mCi) administered every 8 weeks concurrently with the recommended amino acid solution. Adverse reactions observed in NETTER-P were similar to those observed in adults treated with LUTATHERA. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of LUTATHERA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders : hypersensitivity reactions, including angioedema"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"description_table":["
Table 7. Lutetium-177 Main Radiations
RadiationEnergy (keV)Iβ-%Iγ%
β-176.512.2
β-248.10.05
β-384.99.1
β-497.878.6
γ71.60.15
γ112.96.20
γ136.70.05
γ208.411.0
γ249.70.21
γ321.30.22
","
Table 8. Physical Decay Chart: Lutetium-177 Physical Half-Life = 6.647 Days
HoursFraction remainingHoursFraction remaining
01.00048 (2 days)0.812
10.99672 (3 days)0.731
20.991168 (7 days)0.482
50.979336 (14 days)0.232
100.958720 (30 days)0.044
24 (1 day)0.9011080 (45 days)0.009
"],"drug_interactions":["7 DRUG INTERACTIONS Somatostatin Analogs : Discontinue long-acting analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each LUTATHERA dose. ( 2.3 , 7.1 ) 7.1 Somatostatin Analogs Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of LUTATHERA. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each LUTATHERA dose. Administer short- and long-acting octreotide during LUTATHERA treatment as recommended [see Dosage and Administration ( 2.3 )] . 7.2 Glucocorticoids Glucocorticoids can induce down-regulation of subtype 2 somatostatin receptors (SSTR2). Avoid repeated administration of high doses of glucocorticoids during treatment with LUTATHERA."],"mechanism_of_action":["12.1 Mechanism of Action Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta-minus emission from lutetium-177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells."],"recent_major_changes":["Indications and Usage ( 1 ) 4/2024 Dosage and Administration ( 2.2 , 2.5 , 2.6 ) 4/2024 Warnings and Precautions ( 5.1 ) 4/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta-minus emission from lutetium-177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. 12.2 Pharmacodynamics Lutetium Lu 177 dotatate exposure-response relationships and the time course of pharmacodynamics response are unknown. Cardiac Electrophysiology The ability of LUTATHERA to prolong the QTc interval at the recommended dose was assessed in an open-label study in 20 patients with somatostatin receptor-positive midgut carcinoid tumors. No large changes in the mean QTc interval (i.e., > 20 ms) were detected. 12.3 Pharmacokinetics The pharmacokinetics (PK) of lutetium Lu 177 dotatate have been characterized in patients with progressive, somatostatin receptor-positive neuroendocrine tumors. The mean blood exposure (area under the curve) of lutetium Lu 177 dotatate at the recommended dose is 41 ng.h/mL [coefficient of variation (CV) 36%]. The mean maximum blood concentration (C max ) for lutetium Lu 177 dotatate is 10 ng/mL (CV 50%), which generally occurred at the end of the LUTATHERA infusion. Distribution The mean volume of distribution (V z ) for lutetium Lu 177 dotatate is 460 L (CV 54%). The non-radioactive lutetium Lu 175 dotatate is 43% bound to human plasma proteins. Within 4 hours after administration, lutetium Lu 177 dotatate distributes in kidneys, tumor lesions, liver, spleen, and, in some patients, pituitary gland and thyroid. The co-administration of amino acids reduced the median radiation dose to the kidneys by 47% (34% to 59%) and increased the mean beta-phase blood clearance of lutetium Lu 177 dotatate by 36%. Elimination The mean clearance (CL) is 4.5 L/h (CV 31%) and the mean terminal half-life is 71 (±28) hours for lutetium 177 dotatate. Metabolism Lutetium Lu 177 dotatate does not undergo hepatic metabolism. Excretion Lutetium Lu 177 dotatate is primarily eliminated renally with cumulative excretion of 44% within 5 hours, 58% within 24 hours, and 65% within 48 hours following LUTATHERA administration. Prolonged elimination of lutetium Lu 177 dotatate in the urine is expected; however, based on the half-life of lutetium-177 and terminal half-life of lutetium Lu 177 dotatate, greater than 99% of the administered radioactivity will be eliminated within 14 days after administration of LUTATHERA [see Warnings and Precautions ( 5.1 )] . Special Populations Pediatric Patients There were no clinically relevant differences in exposure of lutetium Lu 177 dotatate in pediatric patients 12 years and older compared to that of adult patients. Drug Interaction Studies In Vitro Studies CYP450 enzymes: The non-radioactive lutetium Lu 175 dotatate is not an inhibitor or inducer of cytochrome P450 (CYP) 1A2, 2B6, 2C9, 2C19 or 2D6 in vitro. Transporters: The non-radioactive lutetium Lu 175 dotatate is not an inhibitor of P-glycoprotein, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, or OATP1B3 in vitro."],"indications_and_usage":["1 INDICATIONS AND USAGE LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Risk From Radiation Exposure : Minimize radiation exposure during and after treatment with LUTATHERA consistent with institutional good radiation safety practices and patient management procedures. ( 2.1 , 5.1 ) Myelosuppression : Monitor blood cell counts. Withhold dose, reduce dose, or permanently discontinue based on the severity. ( 2.4 , 5.2 ) Secondary Myelodysplastic Syndrome (MDS) and Leukemia : Median time to onset: MDS is 29 months; acute leukemia is 55 months. ( 5.3 ) Renal Toxicity : Advise patients to hydrate and to urinate frequently before, on the day of and the day after administration of LUTATHERA. Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue based on the severity. ( 2.3 , 2.4 , 5.4 ) Hepatotoxicity : Monitor transaminases, bilirubin, serum albumin and INR. ( 2.4 , 5.5 ) Hypersensitivity Reactions : Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis. Permanently discontinue LUTATHERA based on severity. ( 2.3 , 2.4 , 5.6 ) Neuroendocrine Hormonal Crisis : Monitor for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms. ( 5.7 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise females and males of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.8 , 8.1 , 8.3 ) Risk of Infertility : LUTATHERA may cause infertility. ( 5.9 , 8.3 ) 5.1 Risk From Radiation Exposure LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. These risks of radiation associated with the use of LUTATHERA are greater in pediatric patients than in adults [see Use in Specific Populations ( 8.4 )] . Radiation can be detected in the urine for up to 30 days following LUTATHERA administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.3 )] . 5.2 Myelosuppression In NETTER-1, myelosuppression occurred more frequently in patients receiving LUTATHERA with long-acting octreotide compared to patients receiving high-dose long-acting octreotide (all Grades/Grade 3 or 4): anemia (81%/0) versus (54%/1%); thrombocytopenia (53%/1%) versus (17%/0); and neutropenia (26%/3%) versus (11%/0). In NETTER-1, platelet nadir occurred at a median of 5.1 months following the first dose. Of the 59 patients who developed thrombocytopenia, 68% had platelet recovery to baseline or normal levels. The median time to platelet recovery was 2 months. Fifteen of the nineteen patients in whom platelet recovery was not documented had post-nadir platelet counts. Among these 15 patients, 5 improved to Grade 1, 9 to Grade 2, and 1 to Grade 3. Monitor blood cell counts. Withhold dose, reduce dose, or permanently discontinue LUTATHERA based on the severity of myelosuppression [see Dosage and Administration ( 2.4 )] . 5.3 Secondary Myelodysplastic Syndrome and Leukemia In NETTER-1, with a median follow-up time of 76 months in the main study, myelodysplastic syndrome (MDS) was reported in 2.3% of patients receiving LUTATHERA with long-acting octreotide compared to no patients receiving high-dose long-acting octreotide. In ERASMUS, 16 patients (2.0%) developed MDS and 4 (0.5%) developed acute leukemia. The median time to onset was 29 months (9 to 45 months) for MDS and 55 months (32 to 125 months) for acute leukemia. 5.4 Renal Toxicity In ERASMUS, 8 patients (< 1%) developed renal failure 3 to 36 months following LUTATHERA. Two of these patients had underlying renal impairment or risk factors for renal failure (e.g., diabetes or hypertension) and required dialysis. Administer the recommended amino acid solution before, during and after LUTATHERA [see Dosage and Administration ( 2.3 )] to decrease the reabsorption of lutetium Lu 177 dotatate through the proximal tubules and decrease the radiation dose to the kidneys. Advise patients to hydrate and to urinate frequently before, on the day of, and the day after administration of LUTATHERA. Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue LUTATHERA based on the severity of renal toxicity [see Dosage and Administration ( 2.4 )] . Patients with baseline renal impairment may be at increased risk of toxicity due to increased radiation exposure [see Use in Specific Populations ( 8.6 )] . 5.5 Hepatotoxicity In ERASMUS, 2 patients (< 1%) were reported to have hepatic tumor hemorrhage, edema, or necrosis, with one patient experiencing intrahepatic congestion and cholestasis. Patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure. Monitor transaminases, bilirubin, serum albumin, and international normalized ratio (INR) during treatment. Withhold dose, reduce dose, or permanently discontinue LUTATHERA based on the severity of hepatotoxicity [see Dosage and Administration ( 2.4 )] . 5.6 Hypersensitivity Reactions Hypersensitivity reactions, including angioedema, occurred in patients treated with LUTATHERA [see Adverse Reactions ( 6.2 )] . Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis, during and following LUTATHERA administration for a minimum of 2 hours in a setting where cardiopulmonary resuscitation medication and equipment are available. Discontinue the infusion upon the first observation of any signs or symptoms consistent with a severe hypersensitivity reaction and initiate appropriate therapy. Premedicate patients with a history of Grade 1 or 2 hypersensitivity reactions to LUTATHERA before subsequent doses [see Dosage and Administration ( 2.3 )] . Permanently discontinue LUTATHERA in patients who experience Grade 3 or 4 hypersensitivity reactions [see Dosage and Administration ( 2.4 )] . 5.7 Neuroendocrine Hormonal Crisis Neuroendocrine hormonal crises, manifesting with flushing, diarrhea, bronchospasm and hypotension, occurred in < 1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial LUTATHERA dose. Two (< 1%) patients were reported to have hypercalcemia. Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms of tumor-related hormonal release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated. 5.8 Embryo-Fetal Toxicity Based on its mechanism of action, LUTATHERA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data on LUTATHERA use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from LUTATHERA, can cause fetal harm. Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA [see Dosage and Administration ( 2.1 )] . Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LUTATHERA and for 7 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with LUTATHERA and for 4 months after the last dose [see Use in Specific Populations ( 8.1 , 8.3 )] . 5.9 Risk of Infertility LUTATHERA may cause infertility in males and females. The recommended cumulative dose of 29.6 GBq of LUTATHERA results in a radiation absorbed dose to the testes and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy [see Dosage and Administration ( 2.6 ), Use in Specific Populations ( 8.3 )] ."],"clinical_studies_table":["
Table 9. Efficacy Results in NETTER-1
Abbreviations: CI, confidence interval; IRC, independent radiology committee; NE, not evaluable; NR, not reached; ORR, overall response rate; PFS, progression-free survival. aHazard ratio based on the unstratified Cox model. bUnstratified log rank test. cFisher’s exact test.
LUTATHERA with long-acting Octreotide (30 mg) N = 116Long-acting Octreotide (60 mg) N = 113
PFS by IRC
Events (%)27 (23%)78 (69%)
Progressive disease, n (%) 15 (13%) 61 (54%)
Death, n (%)12 (10%) 17 (15%)
Median in months (95% CI) NR (18.4, NE) 8.5 (6.0, 9.1)
Hazard ratioa (95% CI) 0.21 (0.13, 0.32)
p-valueb< 0.0001
ORR by IRC
ORR, % (95% CI) 13% (7%, 19%) 4% (0.1%, 7%)
Complete response rate, n (%) 1 (1%) 0
Partial response rate, n (%) 14 (12%) 4 (4%)
p-valuec0.0148
Duration of response, median in months (95% CI) NR (2.8, NE) 1.9 (1.9, NE)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity and mutagenicity studies have not been conducted with lutetium Lu 177 dotatate; however, radiation is a carcinogen and mutagen. No animal studies were conducted to determine the effects of lutetium Lu 177 dotatate on fertility. 13.2 Animal Toxicology and/or Pharmacology The primary target organ in animal studies using the non-radioactive lutetium Lu 175 dotatate was the pancreas, a high SSTR2 expressing organ. Pancreatic acinar apoptosis occurred at lutetium Lu 175 dotatate doses ≥ 5 mg/kg in repeat dose toxicology studies in rats. Pancreatic acinar cell atrophy also occurred in repeat dose toxicology studies in dogs at doses ≥ 500 mcg/kg. These findings were consistent with high uptake of the radiolabeled peptide in the pancreas in animal biodistribution studies."],"adverse_reactions_table":["
Table 5. Adverse Reactions Occurring at Higher Incidence in Patients Receiving LUTATHERA with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3-4)a
aNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays adverse reactions occurring at a higher incidence in LUTATHERA-treated patients [between arm difference of ≥ 5% (all Grades) or ≥ 2% (Grades 3-4)]. bIncludes the terms: Glomerular filtration rate decreased, acute kidney injury, acute prerenal failure, azotemia, renal disorder, renal failure, renal impairment. cIncludes the terms: Dysuria, micturition urgency, nocturia, pollakiuria, renal colic, renal pain, urinary tract pain and urinary incontinence.
Adverse reactionaLUTATHERA with long-acting Octreotide (30 mg) (N = 111)Long-acting Octreotide (60 mg) (N = 112)
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
Gastrointestinal disorders
Nausea655122
Vomiting537100
Abdominal pain263193
Diarrhea263181
Constipation10050
General disorders
Fatigue381262
Peripheral edema16091
Pyrexia8030
Metabolism and nutrition disorders
Decreased appetite210113
Nervous system disorders
Headache17050
Dizziness17080
Dysgeusia8020
Vascular disorders
Flushing14190
Hypertension12272
Musculoskeletal and connective tissue disorders
Back pain132100
Pain in extremity11050
Myalgia5000
Neck pain5000
Renal and urinary disorders
Renal failureb13341
Radiation-related urinary tract adverse reactionsc8030
Psychiatric disorders
Anxiety12150
Skin and subcutaneous tissue disorders
Alopecia12020
Respiratory, thoracic and mediastinal disorders
Cough11160
Cardiac disorders
Atrial fibrillation5100
","
Table 6. Laboratory Abnormalities Occurring at Higher Incidence in Patients Receiving LUTATHERA with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3-4)a,b
aValues are worst grade observed after randomization. bNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays laboratory abnormalities occurring at a higher incidence in LUTATHERA-treated patients [between arm difference of ≥ 5% (all Grades) or ≥ 2% (Grades 3-4)].
Laboratory abnormalitybLUTATHERA with long-acting Octreotide (30 mg) (N = 111)Long-acting Octreotide (60 mg) (N = 112)
All Grades %Grades 3-4 %All Grades %Grades 3-4 %
Hematology
Lymphopenia9044395
Anemia810551
Leukopenia552200
Thrombocytopenia531170
Neutropenia263110
Renal/Metabolic
Creatinine increased851730
Hyperglycemia824672
Hyperuricemia346306
Hypocalcemia320140
Hypokalemia264212
Hyperkalemia190110
Hypernatremia17070
Hypoglycemia15080
Hepatic
GGT increased66206716
Alkaline phosphatase increased655559
AST increased505350
ALT increased434340
Blood bilirubin increased302280
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Risk From Radiation Exposure Advise patients and/or caregivers to minimize radiation exposure to household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices and patient management procedures [see Dosage and Administration ( 2.1 ), Warnings and Precautions ( 5.1 )] . Myelosuppression Advise patients and/or caregivers to contact their healthcare provider for any signs or symptoms of myelosuppression or infection [see Warnings and Precautions ( 5.2 )] . Secondary Myelodysplastic Syndrome and Leukemia Advise patients and/or caregivers of the potential for secondary cancers, including myelodysplastic syndrome and acute leukemia [see Warnings and Precautions ( 5.3 )] . Renal Toxicity Advise patients and/or caregivers to hydrate and to urinate frequently before, on the day of, and the day after administration of LUTATHERA [see Warnings and Precautions ( 5.4 )] . Advise patients to contact their healthcare provider for any signs or symptoms of renal toxicity [see Warnings and Precautions ( 5.4 )] . Hepatotoxicity Advise patients and/or caregivers of the need for periodic laboratory tests to monitor for hepatotoxicity [see Warnings and Precautions ( 5.5 )] . Advise patients to contact their healthcare provider for any signs or symptoms of hepatotoxicity [see Warnings and Precautions ( 5.5 )] . Hypersensitivity Advise patients and/or caregivers that LUTATHERA may cause hypersensitivity reactions, including angioedema, and to seek immediate medical attention for signs or symptoms of hypersensitivity [see Warnings and Precautions ( 5.6 )] . Neuroendocrine Hormonal Crises Advise patients and/or caregivers to contact their healthcare provider for signs or symptoms that may occur following tumor-related hormonal release [see Warnings and Precautions ( 5.7 )] . Embryo-Fetal Toxicity Advise pregnant women and males and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.1 , 8.3 )] . Advise females of reproductive potential to use effective contraception during treatment with LUTATHERA and for 7 months after the last dose [see Use in Specific Populations ( 8.1 , 8.3 )] . Advise male patients with female partners of reproductive potential to use effective contraception during treatment with LUTATHERA and for 4 months after the last dose [see Use in Specific Populations ( 8.1 , 8.3 )] . Lactation Advise females not to breastfeed during treatment with LUTATHERA and for 2.5 months after the last dose [see Use in Specific Populations ( 8.2 )] . Infertility Advise female and male patients that LUTATHERA may impair fertility [see Warnings and Precautions ( 5.9 ), Use in Specific Populations ( 8.3 )] . Distributed by: Advanced Accelerator Applications USA, Inc., Millburn, NJ 07041 ©2024 Advanced Accelerator Applications USA, Inc. LUTATHERA ® is a registered trademark of Novartis AG and/or its affiliates. T2024-77"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA. ( 2.1 ) Administer 7.4 GBq (200 mCi) every 8 weeks (± 1 week) for a total of 4 doses. ( 2.2 ) Administer long-acting octreotide 30 mg intramuscularly 4 to 24 hours after each LUTATHERA dose and short-acting octreotide for symptomatic management. ( 2.3 ) Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing LUTATHERA until disease progression or for 18 months following treatment initiation. ( 2.3 ) Administer antiemetics before recommended amino acid solution. ( 2.3 ) Initiate recommended intravenous amino acid solution 30 minutes before LUTATHERA infusion; continue during and for at least 3 hours after LUTATHERA infusion. Do not decrease dose of amino acid solution if LUTATHERA dose is reduced. ( 2.3 ) 2.1 Important Safety Instructions LUTATHERA is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions ( 5.1 )] . Use waterproof gloves and effective radiation shielding when handling LUTATHERA. Radiopharmaceuticals, including LUTATHERA, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals. Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA [see Use in Specific Populations ( 8.1 , 8.3 )] . Monitor patients closely for signs and symptoms of hypersensitivity reactions during and following the LUTATHERA administration for a minimum of 2 hours in a setting where cardiopulmonary resuscitation medication and equipment are available [see Warnings and Precautions ( 5.6 )] . 2.2 Recommended Dosage The recommended LUTATHERA dosage for adult and pediatric patients 12 years and older is 7.4 GBq (200 mCi) every 8 weeks (± 1 week) for a total of 4 doses. Administer premedications and concomitant medications as recommended [see Dosage and Administration ( 2.3 )] . 2.3 Premedications and Concomitant Medications Somatostatin Analogs Before initiating LUTATHERA treatment: Discontinue long-acting somatostatin analogs (e.g., long-acting octreotide) at least 4 weeks prior to initiating LUTATHERA. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating LUTATHERA [see Drug Interactions ( 7.1 )] . During LUTATHERA treatment: Administer long-acting octreotide 30 mg intramuscularly between 4 to 24 hours after each LUTATHERA dose. Do not administer long-acting octreotide within 4 weeks prior to each subsequent LUTATHERA dose. Short-acting octreotide may be given for symptomatic management during LUTATHERA treatment but must be withheld at least 24 hours before each LUTATHERA dose. Following LUTATHERA treatment: Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing LUTATHERA until disease progression or for 18 months following treatment initiation at the discretion of the physician. Antiemetics Administer antiemetics before the recommended amino acid solution. Amino Acid Solution Initiate an intravenous infusion of a sterile amino acid solution containing L-lysine and L-arginine (Table 1) 30 minutes before the start of the LUTATHERA infusion. Use a three-way valve to administer the amino acid solution using the same venous access as LUTATHERA or administer the amino acid solution through a separate venous access in the patient’s other arm. Continue the amino acid solution infusion during and for at least 3 hours after completion of the LUTATHERA infusion. Do not decrease the dose of the amino acid solution if a reduced dose of LUTATHERA is administered [see Warnings and Precautions ( 5.4 )] . Table 1. Amino Acid Solution Item Specification a equivalent to 14.4 to 20 g L-lysine. b equivalent to 14.9 to 20.7 g L-arginine. L-lysine HCl Between 18 and 25 g a L-arginine HCl Between 18 and 25 g b Volume 1 to 2 L Osmolality < 1200 mOsmol/kg Hypersensitivity Prophylaxis Premedicate patients who have had prior Grade 1 or 2 hypersensitivity reactions to LUTATHERA. Do not re-challenge patients who experience Grade 3 or 4 hypersensitivity reactions to LUTATHERA [see Warnings and Precautions ( 5.6 )] . 2.4 Dosage Modifications for Adverse Reactions Recommended dose modifications of LUTATHERA for adverse reactions are provided in Table 2. Table 2. Recommended Dosage Modifications of LUTATHERA for Adverse Reactions a Grading of severity is defined in the most current Common Terminology Criteria for Adverse Events (CTCAE). b Including allergic reaction and anaphylaxis. c No dose modification required for hematological toxicities Grade 3 or Grade 4 solely due to lymphopenia. Adverse reaction Severity of adverse reaction a Dose modification Thrombocytopenia [see Warnings and Precautions ( 5.2 )] First occurrence of Grade 2, 3, or 4 Withhold dose until complete or partial resolution (Grade 0 to 1). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 2, 3, or 4 thrombocytopenia, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for Grade 2 or higher thrombocytopenia requiring a dosing interval beyond 16 weeks. Recurrent Grade 2, 3, or 4 Permanently discontinue LUTATHERA. Anemia and Neutropenia [see Warnings and Precautions ( 5.2 )] First occurrence of Grade 3 or 4 Withhold dose until complete or partial resolution (Grade 0, 1, or 2). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 anemia or neutropenia, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for Grade 3 or higher anemia or neutropenia requiring a dosing interval beyond 16 weeks. Recurrent Grade 3 or 4 Permanently discontinue LUTATHERA. Renal Toxicity [see Warnings and Precautions ( 5.4 )] First occurrence of: Creatinine clearance less than 40 mL/min; calculated using Cockcroft-Gault formula with actual body weight, or 40% increase from baseline serum creatinine, or 40% decrease from baseline creatinine clearance; calculated using Cockcroft-Gault formula with actual body weight. Withhold dose until resolution or return to baseline. Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If reduced dose does not result in renal toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for renal toxicity requiring a dosing interval beyond 16 weeks. Recurrent renal toxicity Permanently discontinue LUTATHERA. Hepatotoxicity [see Warnings and Precautions ( 5.5 )] First occurrence of: Bilirubinemia greater than 3 times the upper limit of normal (Grade 3 or 4), or Serum albumin less than 30 g/L with international normalized ratio (INR) > 1.5. Withhold dose until resolution or return to baseline. Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If reduced LUTATHERA dose does not result in hepatotoxicity, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for hepatotoxicity requiring a dosing interval beyond 16 weeks. Recurrent hepatotoxicity Permanently discontinue LUTATHERA. Hypersensitivity Reactions b [see Warnings and Precautions ( 5.6 )] First occurrence of Grade 3 or 4 Permanently discontinue LUTATHERA. Any Other Adverse Reactions c [see Adverse Reactions ( 6.1 )] First occurrence of Grade 3 or 4 Withhold dose until complete or partial resolution (Grade 0 to 2). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for Grade 3 or higher adverse reactions requiring a dosing interval beyond 16 weeks. Recurrent Grade 3 or 4 Permanently discontinue LUTATHERA. 2.5 Preparation and Administration Preparation Instructions Use aseptic technique and radiation shielding when handling or administering the LUTATHERA solution. Use tongs when handling the vial to minimize radiation exposure. Inspect the product visually under a shielded screen for particulate matter and discoloration prior to administration. Discard the vial if particulates and/or discoloration are present. Do not inject the LUTATHERA solution directly into any other intravenous solution. Confirm the amount of radioactivity of LUTATHERA delivered to the patient with an appropriate dose calibrator prior to and after each LUTATHERA administration. Dispose of any unused medicinal product or waste material in accordance with local and federal laws. Administration Instructions Prior to administration, flush the intravenous catheter used for LUTATHERA administration with ≥ 10 mL of 0.9% Sodium Chloride Injection, USP to ensure patency and to minimize the risk of extravasation. Manage cases of extravasation as per institutional guidelines. The gravity method, peristaltic pump method, or the syringe pump method may be used for the administration of the recommended dosage. Do not administer LUTATHERA as an intravenous bolus. When using the gravity or peristaltic pump method, infuse LUTATHERA directly from its original container. Use the peristaltic pump or syringe pump method when administering a reduced dose of LUTATHERA following a dosage modification for an adverse reaction. When using the gravity method for a reduced dose, adjust the LUTATHERA dose before the administration to avoid the delivery of an incorrect volume of LUTATHERA. Intravenous Methods of Administration Instructions for the Gravity Method Insert a 2.5 cm, 20-gauge needle (short needle) into the LUTATHERA vial and connect via a catheter to 500 mL 0.9% Sodium Chloride Injection, USP (used to transport the LUTATHERA solution during the infusion). Ensure that the short needle does not touch the LUTATHERA solution in the vial and do not connect this short needle directly to the patient. Do not allow the 0.9% Sodium Chloride Injection, USP to flow into the LUTATHERA vial prior to the initiation of the LUTATHERA infusion and do not inject the LUTATHERA solution directly into the 0.9% Sodium Chloride Injection, USP. Insert a second needle that is 9 cm, 18-gauge (long needle) into the LUTATHERA vial ensuring that this long needle touches and is secured to the bottom of the LUTATHERA vial during the entire infusion. Connect the long needle to the patient by an intravenous catheter that is pre-filled with 0.9% Sodium Chloride Injection, USP and that is used for the LUTATHERA infusion into the patient. Use a clamp or an infusion pump to regulate the flow of the 0.9% Sodium Chloride Injection, USP via the short needle into the LUTATHERA vial at a rate of 50 mL/hour to 100 mL/hour for 5 to 10 minutes and then 200 mL/hour to 300 mL/hour for an additional 25 to 30 minutes (the 0.9% Sodium Chloride Injection, USP entering the vial through the short needle will carry the LUTATHERA solution from the vial to the patient via the intravenous catheter connected to the long needle over a total duration of 30 to 40 minutes). During the infusion, ensure that the level of solution in the LUTATHERA vial remains constant. Disconnect the vial from the long needle line and clamp the 0.9% Sodium Chloride Injection, USP line once the level of radioactivity is stable for at least five minutes. Follow the infusion with an intravenous flush of 25 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient. Instructions for the Peristaltic Pump Method Insert a filtered 2.5 cm, 20-gauge needle (short venting needle) into the LUTATHERA vial. Ensure that the short needle does not touch the LUTATHERA solution in the vial and do not connect this short needle directly to the patient or to the peristaltic pump. Insert a second needle that is 9 cm, 18 gauge (long needle) into the LUTATHERA vial ensuring that the long needle touches and is secured to the bottom of the LUTATHERA vial during the entire infusion. Connect the long needle and a 0.9% Sodium Chloride Injection, USP to a 3-way stopcock valve via appropriate tubing. Connect the output of the 3-way stopcock valve to tubing installed on the input side of the peristaltic pump according to manufacturer’s instructions. Prime the line by opening the 3-way stopcock valve and pumping the LUTATHERA solution through the tubing until it reaches the exit of the valve. Prime the intravenous catheter that will be connected to the patient by opening the 3-way stopcock valve to the 0.9% Sodium Chloride Injection, USP and pumping the 0.9% Sodium Chloride Injection, USP until it exits the end of the catheter tubing. Connect the primed intravenous catheter to the patient and set the 3-way stopcock valve such that the LUTATHERA solution is in line with the peristaltic pump. Infuse an appropriate volume of LUTATHERA solution over a 30-40 min period to deliver the desired radioactivity. When the desired LUTATHERA radioactivity has been delivered, stop the peristaltic pump and then change the position of the 3-way stopcock valve so that the peristaltic pump is in line with the 0.9% Sodium Chloride Injection, USP. Restart the peristaltic pump and infuse an intravenous flush of 25 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient. Instructions for the Syringe Pump Method Withdraw an appropriate volume of LUTATHERA solution to deliver the desired radioactivity by using a disposable syringe fitted with a syringe shield and a disposable sterile needle that is 9 cm, 18 gauge (long needle). To aid the withdrawal of the solution, a filtered 2.5 cm, 20-gauge needle (short venting needle) can be used to reduce the resistance from the pressurized vial. Ensure that the short needle does not touch the LUTATHERA solution in the vial. Fit the syringe into the shielded pump and include a 3-way stopcock valve between the syringe and an intravenous catheter pre-filled with 0.9% Sodium Chloride Injection, USP and used for LUTATHERA administration to the patient. Infuse an appropriate volume of LUTATHERA solution over a 30-40 min period to deliver the desired radioactivity. When the desired LUTATHERA radioactivity has been delivered, stop the syringe pump and then change the position of the 3-way stopcock valve to flush the syringe with 25 mL of 0.9% Sodium Chloride Injection, USP. Restart the syringe pump. After the flush of the syringe has been completed, perform an intravenous flush with 25 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient. 2.6 Radiation Dosimetry The maximum penetration of lutetium-177 in tissue is 2.2 mm and the mean penetration is 0.67 mm. The mean and standard deviation (SD) of the estimated radiation absorbed doses for adults receiving LUTATHERA are shown in Table 3. The mean and SD of the estimated radiation absorbed doses for pediatric patients 12 years and older receiving LUTATHERA are shown in Table 4. Table 3. Estimated Radiation Absorbed Dose for LUTATHERA in Adults in NETTER-1 a N = 18 (two patients excluded because the liver absorbed dose was biased by the uptake of the liver metastases). b N = 9 (female patients only). c Red marrow dosimetry estimates were determined using blood radioactivity. d N = 11 (male patients only). Absorbed dose per unit activity (Gy/GBq) (N = 20) Calculated absorbed dose for 4 x 7.4 GBq (29.6 GBq cumulative activity) (Gy) Organ Mean SD Mean SD Adrenals 0.037 0.016 1.1 0.5 Brain 0.027 0.016 0.8 0.5 Breasts 0.027 0.015 0.8 0.4 Gallbladder wall 0.042 0.019 1.2 0.6 Heart wall 0.032 0.015 0.9 0.4 Kidneys 0.654 0.295 19.4 8.7 Liver a 0.299 0.226 8.9 6.7 Lower large intestine wall 0.029 0.016 0.9 0.5 Lungs 0.031 0.015 0.9 0.4 Muscle 0.029 0.015 0.8 0.4 Osteogenic cells 0.151 0.268 4.5 7.9 Ovaries b 0.031 0.013 0.9 0.4 Pancreas 0.038 0.016 1.1 0.5 Red marrow c 0.035 0.029 1.0 0.8 Skin 0.027 0.015 0.8 0.4 Small intestine 0.031 0.015 0.9 0.5 Spleen 0.846 0.804 25.1 23.8 Stomach wall 0.032 0.015 0.9 0.5 Testes d 0.026 0.018 0.8 0.5 Thymus 0.028 0.015 0.8 0.5 Thyroid 0.027 0.016 0.8 0.5 Total body 0.052 0.027 1.6 0.8 Upper large intestine wall 0.032 0.015 0.9 0.4 Urinary bladder wall 0.437 0.176 12.8 5.3 Uterus b 0.032 0.013 1.0 0.4 Table 4. Estimated Radiation Absorbed Dose for LUTATHERA in Pediatric Patients 12 Years and Older in NETTER-P a Data are pooled for 8 pediatric patients with somatostatin receptor-positive (SSTR+) tumors, including 4 patients with GEP-NETs. b N = 5 (female patients only). c N = 7 (3 GEP-NET, 4 SSTR+ tumors). Pituitary dosimetry estimates were only performed when pituitary uptake was clearly observed on the planar images. Due to the small size of the pituitary gland, availability for quantification only from planar images and interference from activity in the nasal mucosa, estimates can be associated with a large uncertainty. Pituitary gland absorbed dose estimate includes absorbed dose contributions from activity within the pituitary only, dose contributions from other tissues are not included. d N = 3 (male patients only). e Red marrow dosimetry estimates were determined either using blood radioactivity or by imaging and scaling of a representative region of the lumbar spine. Absorbed dose per unit activity (Gy/GBq) (N = 8 a ) Calculated absorbed dose for 4 x 7.4 GBq (29.6 GBq cumulative activity) (Gy) Organ Mean SD Mean SD Adrenals 0.045 0.011 1.3 0.3 Brain 0.021 0.006 0.6 0.2 Breasts b 0.018 0.006 0.5 0.2 Esophagus 0.024 0.006 0.7 0.2 Eyes 0.021 0.006 0.6 0.2 Gallbladder wall 0.031 0.011 0.9 0.3 Heart wall 0.024 0.006 0.7 0.2 Kidneys 0.773 0.288 22.9 8.5 Left colon 0.265 0.081 7.8 2.4 Liver 0.216 0.231 6.4 6.8 Lungs 0.024 0.006 0.7 0.2 Osteogenic cells 0.046 0.019 1.4 0.6 Ovaries b 0.026 0.007 0.8 0.2 Pancreas 0.027 0.007 0.8 0.2 Pituitary c 1.053 0.348 31.2 10.3 Prostate d 0.026 0.006 0.8 0.2 Rectum 0.272 0.085 8.0 2.5 Red marrow (blood) e 0.027 0.005 0.8 0.2 Red marrow (image) e 0.055 0.026 1.6 0.8 Right colon 0.152 0.045 4.5 1.3 Salivary glands 0.036 0.017 1.1 0.5 Small intestine 0.046 0.013 1.3 0.4 Spleen 0.733 0.304 21.7 9.0 Stomach wall 0.027 0.007 0.8 0.2 Testes d 0.021 0.005 0.6 0.2 Thymus 0.022 0.006 0.7 0.2 Thyroid 0.022 0.006 0.6 0.2 Total body 0.042 0.010 1.2 0.3 Urinary bladder wall 0.573 0.088 17.0 2.6 Uterus b 0.031 0.008 0.9 0.2"],"spl_product_data_elements":["Lutathera Lutetium Lu 177 dotatate ACETIC ACID SODIUM ACETATE GENTISIC ACID SODIUM HYDROXIDE PENTETIC ACID SODIUM CHLORIDE ASCORBIC ACID WATER LUTETIUM OXODOTREOTIDE LU-177 LUTETIUM OXODOTREOTIDE LU-177"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 370 MBq/mL (10 mCi/mL) of lutetium Lu 177 dotatate as a clear and colorless to slightly yellow solution in a single-dose vial. Injection: 370 MBq/mL (10 mCi/mL) in single-dose vial. ( 3 )"],"recent_major_changes_table":["
Indications and Usage (1)4/2024
Dosage and Administration (2.2, 2.5, 2.6)4/2024
Warnings and Precautions (5.1)4/2024
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on its mechanism of action, LUTATHERA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data on LUTATHERA use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from LUTATHERA, can cause fetal harm. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary There are no data on the presence of lutetium Lu 177 dotatate in human milk, or its effects on the breastfed child or milk production. No lactation studies in animals were conducted. Because of the potential risk for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LUTATHERA and for 2.5 months after the last dose. 8.3 Females and Males of Reproductive Potential Based on mechanism of action, LUTATHERA can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA [see Use in Specific Populations ( 8.1 )] . Contraception Females Advise females of reproductive potential to use effective contraception during treatment with LUTATHERA and for 7 months after the last dose. Males Advise males with female partners of reproductive potential to use effective contraception during treatment with LUTATHERA and for 4 months after the last dose [see Clinical Pharmacology ( 12.1 ), Nonclinical Toxicology ( 13.1 )] . Infertility The recommended cumulative dose of 29.6 GBq of LUTATHERA results in a radiation absorbed dose to the testes and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy [see Dosage and Administration ( 2.6 )] . 8.4 Pediatric Use Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors The safety and effectiveness of LUTATHERA have been established in pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Use of LUTATHERA for this indication is supported by evidence from an adequate and well-controlled study of LUTATHERA in adults with additional safety, pharmacokinetic, and dosimetry data in pediatric patients aged 12 years and older with somatostatin receptor-positive tumors, including 4 pediatric patients with GEP-NETs [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), Clinical Studies ( 14 )] . The risks of radiation exposure associated with LUTATHERA are greater in pediatric patients than in adult patients due to longer life expectancy. Continued follow-up is recommended for evaluation of long-term effects. There was no clinically relevant difference in lutetium Lu 177 dotatate exposure in pediatric patients aged 13 to 16 years versus adult patients [see Clinical Pharmacology ( 12.3 )] . The pharmacokinetic profile and safety of LUTATHERA in pediatric patients 12 years and older with baseline renal impairment have not been studied. The safety and effectiveness of LUTATHERA have not been established in pediatric patients younger than 12 years old with somatostatin receptor-positive GEP-NETs. 8.5 Geriatric Use Of the 1325 patients treated with LUTATHERA in clinical trials, 438 patients (33%) were 65 years and older. No overall differences in safety or effectiveness were observed between older and younger patients. 8.6 Renal Impairment No dose adjustment is recommended for patients with baseline mild to moderate (creatinine clearance 30 to 89 mL/min by Cockcroft-Gault formula) renal impairment. However, patients with baseline mild or moderate renal impairment may be at greater risk of toxicity, including renal toxicity, due to increased radiation exposure. Perform more frequent assessments of renal function in patients with baseline mild to moderate impairment. The pharmacokinetic profile and safety of LUTATHERA in patients with baseline severe renal impairment (creatinine clearance < 30 mL/min by Cockcroft-Gault formula) or end-stage renal disease have not been studied [see Warnings and Precautions ( 5.4 )] . 8.7 Hepatic Impairment No dose adjustment is recommended for patients with baseline mild or moderate hepatic impairment. The pharmacokinetic profile and safety of LUTATHERA in patients with baseline severe hepatic impairment (total bilirubin > 3 times upper limit of normal, regardless of AST level) have not been studied."],"dosage_and_administration_table":["
Table 1. Amino Acid Solution
ItemSpecification
aequivalent to 14.4 to 20 g L-lysine. bequivalent to 14.9 to 20.7 g L-arginine.
L-lysine HClBetween 18 and 25 ga
L-arginine HClBetween 18 and 25 gb
Volume1 to 2 L
Osmolality< 1200 mOsmol/kg
","
Table 2. Recommended Dosage Modifications of LUTATHERA for Adverse Reactions
aGrading of severity is defined in the most current Common Terminology Criteria for Adverse Events (CTCAE). bIncluding allergic reaction and anaphylaxis. cNo dose modification required for hematological toxicities Grade 3 or Grade 4 solely due to lymphopenia.
Adverse reactionSeverity of adverse reactionaDose modification
Thrombocytopenia [see Warnings and Precautions (5.2)]First occurrence of Grade 2, 3, or 4Withhold dose until complete or partial resolution (Grade 0 to 1). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 2, 3, or 4 thrombocytopenia, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for Grade 2 or higher thrombocytopenia requiring a dosing interval beyond 16 weeks.
Recurrent Grade 2, 3, or 4Permanently discontinue LUTATHERA.
Anemia and Neutropenia [see Warnings and Precautions (5.2)]First occurrence of Grade 3 or 4Withhold dose until complete or partial resolution (Grade 0, 1, or 2). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 anemia or neutropenia, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for Grade 3 or higher anemia or neutropenia requiring a dosing interval beyond 16 weeks.
Recurrent Grade 3 or 4Permanently discontinue LUTATHERA.
Renal Toxicity [see Warnings and Precautions (5.4)]First occurrence of:Creatinine clearance less than 40 mL/min; calculated using Cockcroft-Gault formula with actual body weight, or40% increase from baseline serum creatinine, or40% decrease from baseline creatinine clearance; calculated using Cockcroft-Gault formula with actual body weight.Withhold dose until resolution or return to baseline. Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If reduced dose does not result in renal toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for renal toxicity requiring a dosing interval beyond 16 weeks.
Recurrent renal toxicityPermanently discontinue LUTATHERA.
Hepatotoxicity [see Warnings and Precautions (5.5)]First occurrence of:Bilirubinemia greater than 3 times the upper limit of normal (Grade 3 or 4), orSerum albumin less than 30 g/L with international normalized ratio (INR) > 1.5.Withhold dose until resolution or return to baseline. Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If reduced LUTATHERA dose does not result in hepatotoxicity, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for hepatotoxicity requiring a dosing interval beyond 16 weeks.
Recurrent hepatotoxicityPermanently discontinue LUTATHERA.
Hypersensitivity Reactionsb [see Warnings and Precautions (5.6)]First occurrence of Grade 3 or 4Permanently discontinue LUTATHERA.
Any Other Adverse Reactionsc [see Adverse Reactions (6.1)]First occurrence of Grade 3 or 4Withhold dose until complete or partial resolution (Grade 0 to 2). Resume LUTATHERA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 toxicity, administer LUTATHERA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue LUTATHERA for Grade 3 or higher adverse reactions requiring a dosing interval beyond 16 weeks.
Recurrent Grade 3 or 4Permanently discontinue LUTATHERA.
","
Table 3. Estimated Radiation Absorbed Dose for LUTATHERA in Adults in NETTER-1
aN = 18 (two patients excluded because the liver absorbed dose was biased by the uptake of the liver metastases). bN = 9 (female patients only). cRed marrow dosimetry estimates were determined using blood radioactivity. dN = 11 (male patients only).
Absorbed dose per unit activity (Gy/GBq)(N = 20)Calculated absorbed dose for 4 x 7.4 GBq(29.6 GBq cumulative activity)(Gy)
OrganMeanSDMeanSD
Adrenals0.0370.0161.10.5
Brain0.0270.0160.80.5
Breasts0.0270.0150.80.4
Gallbladder wall0.0420.0191.20.6
Heart wall0.0320.0150.90.4
Kidneys0.6540.29519.48.7
Livera0.2990.2268.96.7
Lower large intestine wall0.0290.0160.90.5
Lungs0.0310.0150.90.4
Muscle0.0290.0150.80.4
Osteogenic cells0.1510.2684.57.9
Ovariesb0.0310.0130.90.4
Pancreas0.0380.0161.10.5
Red marrowc0.0350.0291.00.8
Skin0.0270.0150.80.4
Small intestine0.0310.0150.90.5
Spleen0.8460.80425.123.8
Stomach wall0.0320.0150.90.5
Testesd0.0260.0180.80.5
Thymus0.0280.0150.80.5
Thyroid0.0270.0160.80.5
Total body0.0520.0271.60.8
Upper large intestine wall0.0320.0150.90.4
Urinary bladder wall0.4370.17612.85.3
Uterusb0.0320.0131.00.4
","
Table 4. Estimated Radiation Absorbed Dose for LUTATHERA in Pediatric Patients 12 Years and Older in NETTER-P
aData are pooled for 8 pediatric patients with somatostatin receptor-positive (SSTR+) tumors, including 4 patients with GEP-NETs. bN = 5 (female patients only). cN = 7 (3 GEP-NET, 4 SSTR+ tumors). Pituitary dosimetry estimates were only performed when pituitary uptake was clearly observed on the planar images. Due to the small size of the pituitary gland, availability for quantification only from planar images and interference from activity in the nasal mucosa, estimates can be associated with a large uncertainty. Pituitary gland absorbed dose estimate includes absorbed dose contributions from activity within the pituitary only, dose contributions from other tissues are not included. dN = 3 (male patients only). eRed marrow dosimetry estimates were determined either using blood radioactivity or by imaging and scaling of a representative region of the lumbar spine.
Absorbed dose per unit activity (Gy/GBq)(N = 8a)Calculated absorbed dose for 4 x 7.4 GBq(29.6 GBq cumulative activity)(Gy)
OrganMeanSDMeanSD
Adrenals0.0450.0111.30.3
Brain0.0210.0060.60.2
Breastsb0.0180.0060.50.2
Esophagus0.0240.0060.70.2
Eyes0.0210.0060.60.2
Gallbladder wall0.0310.0110.90.3
Heart wall0.0240.0060.70.2
Kidneys0.7730.28822.98.5
Left colon0.2650.0817.82.4
Liver0.2160.2316.46.8
Lungs0.0240.0060.70.2
Osteogenic cells0.0460.0191.40.6
Ovariesb0.0260.0070.80.2
Pancreas0.0270.0070.80.2
Pituitaryc1.0530.34831.210.3
Prostated0.0260.0060.80.2
Rectum0.2720.0858.02.5
Red marrow (blood)e0.0270.0050.80.2
Red marrow (image) e0.0550.0261.60.8
Right colon0.1520.0454.51.3
Salivary glands0.0360.0171.10.5
Small intestine0.0460.0131.30.4
Spleen0.7330.30421.79.0
Stomach wall0.0270.0070.80.2
Testesd0.0210.0050.60.2
Thymus 0.0220.0060.70.2
Thyroid0.0220.0060.60.2
Total body0.0420.0101.20.3
Urinary bladder wall0.5730.08817.02.6
Uterusb0.0310.0080.90.2
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology The primary target organ in animal studies using the non-radioactive lutetium Lu 175 dotatate was the pancreas, a high SSTR2 expressing organ. Pancreatic acinar apoptosis occurred at lutetium Lu 175 dotatate doses ≥ 5 mg/kg in repeat dose toxicology studies in rats. Pancreatic acinar cell atrophy also occurred in repeat dose toxicology studies in dogs at doses ≥ 500 mcg/kg. These findings were consistent with high uptake of the radiolabeled peptide in the pancreas in animal biodistribution studies."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL Lutathera ® lutetium Lu 177 dotatate injection For Intravenous Infusion Single-dose vial. Discard after 72 hours. Rx Only NDC 69488-003-01 NOVARTIS PRINCIPAL DISPLAY PANEL Lutathera® lutetium Lu 177 dotatate injection For Intravenous Infusion Single-dose vial. Discard after 72 hours. Rx Only NDC 69488-003-01 NOVARTIS"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity and mutagenicity studies have not been conducted with lutetium Lu 177 dotatate; however, radiation is a carcinogen and mutagen. No animal studies were conducted to determine the effects of lutetium Lu 177 dotatate on fertility."]},"tags":[{"label":"Peptide","category":"modality"},{"label":"Somatostatin receptor type 2","category":"target"},{"label":"SSTR2","category":"gene"},{"label":"V10XX04","category":"atc"},{"label":"Active","category":"status"},{"label":"Neuroendocrine tumor","category":"indication"},{"label":"Aaa Usa Inc","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Diagnostic Uses of Chemicals","category":"pharmacology"},{"label":"Indicators and Reagents","category":"pharmacology"},{"label":"Radiopharmaceuticals","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":4353.432,"date":"","count":998,"signal":"Ill-defined disorder","source":"DrugCentral FAERS","actionTaken":"Reported 998 times (LLR=4353)"},{"llr":309.948,"date":"","count":107,"signal":"Laboratory test abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=310)"},{"llr":273.544,"date":"","count":150,"signal":"COVID-19","source":"DrugCentral FAERS","actionTaken":"Reported 150 times (LLR=274)"},{"llr":272.321,"date":"","count":106,"signal":"Illness","source":"DrugCentral FAERS","actionTaken":"Reported 106 times (LLR=272)"},{"llr":194.961,"date":"","count":128,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 128 times (LLR=195)"},{"llr":189.157,"date":"","count":212,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 212 times (LLR=189)"},{"llr":163.993,"date":"","count":102,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 102 times (LLR=164)"},{"llr":148.971,"date":"","count":59,"signal":"Metastases to liver","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=149)"},{"llr":114.117,"date":"","count":95,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 95 times (LLR=114)"},{"llr":93.384,"date":"","count":33,"signal":"SARS-CoV-2 test positive","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=93)"},{"llr":53.407,"date":"","count":11,"signal":"Blood chromogranin A increased","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=53)"},{"llr":47.821,"date":"","count":12,"signal":"Neuroendocrine tumour","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=48)"},{"llr":47.667,"date":"","count":68,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 68 times (LLR=48)"},{"llr":46.378,"date":"","count":17,"signal":"Hepatic lesion","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=46)"},{"llr":45.511,"date":"","count":25,"signal":"Metastases to bone","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=46)"}],"commonSideEffects":[{"effect":"Ill-defined disorder","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Laboratory test abnormal","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"COVID-19","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Illness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Platelet count decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Metastases to liver","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Disease progression","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"SARS-CoV-2 test positive","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood chromogranin A increased","drugRate":"LLR 53","severity":"common","_validated":true},{"effect":"Neuroendocrine tumour","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hepatic lesion","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Metastases to bone","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}]},"trials":[],"aliases":[],"company":"Aaa Usa Inc","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2038-07-25","territory":"US","patentNumber":"10596276"},{"source":"FDA Orange Book via DrugCentral","expires":"2038-07-25","territory":"US","patentNumber":"10596278"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=lutetium (177Lu) oxodotreotide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:43:15.248052+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:43:15.247975+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Lutetium (177Lu) Oxodotreotide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:43:23.113592+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:43:21.639240+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:43:15.316572+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lutetium (177Lu) oxodotreotide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:43:22.061109+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:13.847134+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:13.847157+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Somatostatin receptor binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:43:23.113532+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297545/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:43:22.774669+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208700","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:13.847161+00:00"}},"allNames":"lutathera","offLabel":[],"synonyms":["lutetium (177Lu) oxodotreotide","lutetium Lu 177 dotatate","lutathera"],"timeline":[{"date":"2017-09-26","type":"positive","source":"DrugCentral","milestone":"EMA approval (Advanced Accelerator Applications)"},{"date":"2018-01-26","type":"positive","source":"DrugCentral","milestone":"FDA approval (Aaa Usa Inc)"},{"date":"2021-06-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (FUJIFILM TOYAMA CHEMICAL Co., Ltd.)"}],"aiSummary":"Lutathera (lutetium (177Lu) oxodotreotide) is a small molecule radiopharmaceutical that targets somatostatin receptor type 2. It is used to treat neuroendocrine tumors and was originally developed by AAA USA INC, with the current owner also being AAA USA INC. Lutathera was FDA approved in 2018 and is a patented product. Key safety considerations include radiation exposure and potential effects on bone marrow and kidneys. It is essential to monitor patients for these potential side effects.","approvals":[{"date":"2017-09-26","orphan":true,"company":"Advanced Accelerator Applications","regulator":"EMA"},{"date":"2018-01-26","orphan":true,"company":"AAA USA INC","regulator":"FDA"},{"date":"2021-06-23","orphan":false,"company":"FUJIFILM TOYAMA CHEMICAL Co., Ltd.","regulator":"PMDA"}],"brandName":"Lutathera","ecosystem":[{"indication":"Neuroendocrine tumor","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Somatostatin receptor type 2","novelty":"Follow-on","targets":[{"gene":"SSTR2","source":"DrugCentral","target":"Somatostatin receptor type 2","protein":"Somatostatin receptor type 2"}],"modality":"Peptide","explanation":"Imagine a key that fits into a lock on the surface of cancer cells. Lutathera is like that key, which binds to a specific receptor on the surface of neuroendocrine tumor cells. Once bound, it delivers a small amount of radiation that kills the cell.","oneSentence":"Lutathera works by binding to somatostatin receptors on neuroendocrine tumor cells, delivering a radioactive dose that kills the cells.","technicalDetail":"Lutathera is a somatostatin receptor-targeted radiopharmaceutical that utilizes the high affinity of somatostatin analogs for somatostatin receptors to deliver a therapeutic dose of 177Lu to neuroendocrine tumor cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lutetium_(177Lu)_oxodotreotide","title":"Lutetium (177Lu) oxodotreotide","extract":"Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. It is a radiolabeled somatostatin analog.","wiki_history":"== History ==\nThe European Commission approved lutetium (177Lu) oxodotreotide (brand name Lutathera) \"for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults\" in September 2017.\n\n177Lu dotatate was approved in the United States for the treatment of SSTR positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults, in January 2018. This was the first time a radiopharmaceutical had been approved for the treatment of GEP-NETs in the United States. Enrolled participants had tumors which could not be surgically removed and were worsening while receiving treatment with octreotide. It was approved for adults in 2018.\n\nApproval for children aged 12 years and older was based on pharmacokinetic, dosimetry, and safety data from NETTER-P (NCT04711135), an ongoing, international, multi-center, open-label, single-arm study of lutetium Lu 177 dotatate in adolescents with locally advanced/inoperable or metastatic SSTR-positive gastroenteropancreatic neuroendocrine tumors or pheochromocytoma/paraganglioma. Approval was also based on the extrapolation of efficacy outcomes observed in NETTER-1 (NCT01578239), a randomized, multicenter, open-label, active-controlled trial in 229 participants with locally advanced/inoperable or metastatic SSTR-positive midgut carcinoid tumors, which supported the original approval of lutetium Lu 177 dotatate in adults.\n\nSafety was evaluated in nine pediatric participants in NETTER-P, including four participants with gastroenteropancreatic neuroendocrine tumors. The major outcome measures were absorbed radiation doses in target organs and incidence of adverse reactions after the first treatment cycle. Additional outcome measures included short-term adverse reactions following treatment with lutetium Lu 177 dotatate. The adver"},"commercial":{"launchDate":"2018","revenueYear":2025,"_launchSource":"DrugCentral (FDA 2018-01-26, AAA USA INC)","annualRevenue":190,"revenueSource":"SEC 8-K Novartis (2024-10-29)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:49.860452","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5275","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=lutetium%20%28177Lu%29%20oxodotreotide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lutetium (177Lu) oxodotreotide","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Lutetium_(177Lu)_oxodotreotide","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T14:11:35.588432","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:26.439421+00:00","fieldsConflicting":12,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"sodium phosphate (32P)","drugSlug":"sodium-phosphate-(32p)","fdaApproval":"1959-03-04","relationship":"same-class"},{"drugName":"ibritumomab tiuxetan","drugSlug":"ibritumomab-tiuxetan","fdaApproval":"2002-02-19","relationship":"same-class"},{"drugName":"radium Ra 223 dichloride","drugSlug":"radium-ra-223-dichloride","fdaApproval":"2013-05-15","relationship":"same-class"},{"drugName":"lutetium (177Lu) vipivotide tetraxetan","drugSlug":"lutetium-(177lu)-vipivotide-tetraxetan","fdaApproval":"2022-03-23","relationship":"same-class"}],"genericName":"lutetium (177lu) oxodotreotide","indications":{"approved":[{"name":"Neuroendocrine tumor","source":"DrugCentral","snomedId":255046005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"sodium-phosphate-(32p)","brandName":"sodium phosphate (32P)","genericName":"sodium phosphate (32P)","approvalYear":"1959","relationship":"same-class"},{"drugId":"ibritumomab-tiuxetan","brandName":"ibritumomab tiuxetan","genericName":"ibritumomab tiuxetan","approvalYear":"2002","relationship":"same-class"},{"drugId":"radium-ra-223-dichloride","brandName":"radium Ra 223 dichloride","genericName":"radium Ra 223 dichloride","approvalYear":"2013","relationship":"same-class"},{"drugId":"lutetium-(177lu)-vipivotide-tetraxetan","brandName":"lutetium (177Lu) vipivotide tetraxetan","genericName":"lutetium (177Lu) vipivotide tetraxetan","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":["Metastatic Pancreatic Neuroendocrine Tumor","Pancreatic Neoplasm","Stage III Pancreatic Neuroendocrine Tumor AJCC v8","Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","Unresectable Pancreatic Neuroendocrine Tumor"],"enrollment":24,"completionDate":"2026-12-14"},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":["Advanced Lung Neuroendocrine Tumor","Functioning Lung Neuroendocrine Tumor","Locally Advanced Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Tumor G1","Lung Neuroendocrine Tumor G2","Metastatic Lung Neuroendocrine Neoplasm","Metastatic Lung Neuroendocrine Tumor","Non-Functioning Lung Neuroendocrine Tumor","Recurrent Lung Neuroendocrine Neoplasm","Unresectable Lung Neuroendocrine Neoplasm","Unresectable Lung Neuroendocrine Tumor"],"enrollment":70,"completionDate":"2033-01-16"},{"nctId":"NCT04261855","phase":"PHASE1,PHASE2","title":"Targeted Therapy and Avelumab in Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2020-10-08","conditions":["Metastatic Merkel Cell Carcinoma"],"enrollment":19,"completionDate":"2027-12"},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":["Metastatic Digestive System Neuroendocrine Tumor G1","Metastatic Digestive System Neuroendocrine Tumor G2","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2"],"enrollment":100,"completionDate":"2026-04-30"},{"nctId":"NCT04750954","phase":"PHASE1","title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-22","conditions":["Neuroendocrine Neoplasm"],"enrollment":29,"completionDate":"2026-06-30"},{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":["Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation","Metastatic Prostate Neuroendocrine Carcinoma","Metastatic Prostate Small Cell Neuroendocrine Carcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2026-11-02"},{"nctId":"NCT05724108","phase":"PHASE2","title":"Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-30","conditions":["Metastatic Neuroendocrine Tumor"],"enrollment":94,"completionDate":"2026-12-09"},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":["Intracranial Meningioma"],"enrollment":153,"completionDate":"2030-08"},{"nctId":"NCT04727723","phase":"","title":"Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-09","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":164,"completionDate":"2026-03-31"},{"nctId":"NCT06122610","phase":"PHASE1","title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2025-03-07","conditions":["Neuroendocrine Tumors","Somatostatin Receptor-positive Neuroendocrine Tumor"],"enrollment":10,"completionDate":"2026-06"},{"nctId":"NCT05142696","phase":"PHASE1,PHASE2","title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-13","conditions":["Extensive Stage Small Cell Lung Cancer"],"enrollment":24,"completionDate":"2029-03-23"},{"nctId":"NCT05109728","phase":"PHASE1","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":["Glioblastoma"],"enrollment":65,"completionDate":"2027-07-31"},{"nctId":"NCT03971461","phase":"PHASE2","title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-05-15","conditions":["Meningioma"],"enrollment":32,"completionDate":"2027-01"},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":["Somatostatin Receptor Positive (SSTR+)","Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)"],"enrollment":240,"completionDate":"2034-01-05"},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":["Digestive System Neuroendocrine Tumor","Unresectable Digestive System Neuroendocrine Neoplasm","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2"],"enrollment":15,"completionDate":"2027-09-30"},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":["Pheochromocytoma","Paraganglioma","Neuroendocrine Tumors","Neuroendocrine Neoplasms"],"enrollment":130,"completionDate":"2033-01-01"},{"nctId":"NCT04711135","phase":"PHASE2","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2022-08-31","conditions":["Gastroenteropancreatic Neuroendocrine Tumors","Pheochromocytoma","Paraganglioma"],"enrollment":11,"completionDate":"2034-02-06"},{"nctId":"NCT04954820","phase":"PHASE2","title":"Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-10-18","conditions":["Neuroendocrine Tumors","Intestinal Well Differentiated Endocrine Tumor","Progressive Disease"],"enrollment":146,"completionDate":"2031-10"},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":["Gastro-enteropancreatic Neuroendocrine Tumor"],"enrollment":226,"completionDate":"2027-10-29"},{"nctId":"NCT05987176","phase":"PHASE2","title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2024-08-02","conditions":["Neuroendocrine Tumor G1 (NET G1)/Carcinoid","Neuroendocrine Tumor Grade 2","Neuroendocrine Tumors","Liver Metastases","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Neoplasm"],"enrollment":1,"completionDate":"2025-10-21"},{"nctId":"NCT06663072","phase":"PHASE1","title":"Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-12-13","conditions":["Metastatic Pancreatic Neuroendocrine Tumor"],"enrollment":25,"completionDate":"2026-11"},{"nctId":"NCT03691064","phase":"","title":"Post-Authorization Long-Term Safety Study of LUTATHERA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2018-11-28","conditions":["Neuroendocrine Tumors"],"enrollment":1014,"completionDate":"2027-09-30"},{"nctId":"NCT04234568","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":["Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Neuroendocrine Tumor"],"enrollment":31,"completionDate":"2026-03-14"},{"nctId":"NCT05844332","phase":"","title":"LUTATHERA Injection General Use Result Survey","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":["Somatostatin Receptor-positive Neuroendocrine Tumor"],"enrollment":347,"completionDate":"2024-06-27"},{"nctId":"NCT04086485","phase":"PHASE1,PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-03","conditions":["Gastroenteropancreatico Tumors","Neuroendocrine Tumors","Neuroendocrine Neoplasms"],"enrollment":56,"completionDate":"2028-01-01"},{"nctId":"NCT06016855","phase":"PHASE4","title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2024-05-31","conditions":["Digestive System Neuroendocrine Tumor G1","Digestive System Neuroendocrine Tumor G2","Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Malignant Neoplasm in the Liver","Pancreatic Neuroendocrine Tumor G1","Pancreatic Neuroendocrine Tumor G2"],"enrollment":6,"completionDate":"2028-05-28"},{"nctId":"NCT04082520","phase":"PHASE2","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-04-14","conditions":["Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Recurrent Meningioma","Unresectable Meningioma"],"enrollment":41,"completionDate":"2031-01-06"},{"nctId":"NCT02743741","phase":"NA","title":"Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2016-07-15","conditions":["Neuroendocrine Tumors"],"enrollment":195,"completionDate":"2026-06"},{"nctId":"NCT05178693","phase":"PHASE1","title":"Lutathera and ASTX727 in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2022-04-25","conditions":["Neuroendocrine Tumors"],"enrollment":27,"completionDate":"2029-02-28"},{"nctId":"NCT03966651","phase":"PHASE1","title":"A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2023-04-17","conditions":["Neuroblastoma"],"enrollment":18,"completionDate":"2026-09"},{"nctId":"NCT04529044","phase":"PHASE2","title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-01","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma"],"enrollment":10,"completionDate":"2026-12-20"},{"nctId":"NCT05278208","phase":"PHASE1,PHASE2","title":"Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-21","conditions":["High Grade Glioma","Meningioma","Embryonal Tumor","Medulloblastoma","Anaplastic Ependymoma","Recurrent Diffuse Intrinsic Pontine Glioma","Recurrent Malignant Glioma","Recurrent Medulloblastoma","Recurrent Primary Central Nervous System Neoplasm","Refractory Diffuse Intrinsic Pontine Glioma","Refractory Malignant Glioma","Refractory Medulloblastoma","Refractory Primary Central Nervous System Neoplasm"],"enrollment":65,"completionDate":"2027-11"},{"nctId":"NCT07185672","phase":"PHASE3","title":"PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2019-08-07","conditions":["Neuroendocrine Neoplasia's (NENs)","Neuroendocrine Tumor GEP Grade 1-3","Neuroendocrine Gastroenteropancreatic Tumour"],"enrollment":162,"completionDate":"2027-08-07"},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":["Recurrent Meningioma"],"enrollment":136,"completionDate":"2028-12-22"},{"nctId":"NCT04609592","phase":"PHASE1","title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-03-17","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":10,"completionDate":"2027-09"},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":["Neuroendocrine Tumors"],"enrollment":196,"completionDate":"2028-12"},{"nctId":"NCT06398444","phase":"PHASE2,PHASE3","title":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2024-06-11","conditions":["Advanced Neuroendocrine Neoplasm"],"enrollment":74,"completionDate":"2029-06-01"},{"nctId":"NCT03457948","phase":"PHASE2","title":"Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas Fidelman, MD","startDate":"2018-08-27","conditions":["Metastatic Malignant Neoplasm in the Liver","Neuroendocrine Neoplasm"],"enrollment":32,"completionDate":"2026-05-31"},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":["Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)"],"enrollment":166,"completionDate":"2029-01"},{"nctId":"NCT01876771","phase":"PHASE2","title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2014-04-29","conditions":["Carcinoma, Neuroendocrine"],"enrollment":500,"completionDate":"2042-12"},{"nctId":"NCT06395402","phase":"PHASE2","title":"177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry","status":"RECRUITING","sponsor":"University of Iowa","startDate":"2024-05-03","conditions":["Neuroendocrine Tumors","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2"],"enrollment":120,"completionDate":"2029-12-31"},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":["NETS Ga68 Lu177"],"enrollment":184,"completionDate":"2027-02-24"},{"nctId":"NCT07012330","phase":"PHASE2","title":"Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2007-03-01","conditions":["Neuroendocrine (NE) Tumors"],"enrollment":111,"completionDate":"2015-12-31"},{"nctId":"NCT05583708","phase":"PHASE2","title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-08-03","conditions":["Merkel Cell Carcinoma"],"enrollment":18,"completionDate":"2026-09"},{"nctId":"NCT04544098","phase":"EARLY_PHASE1","title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":["Neuroendocrine Tumors","Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors"],"enrollment":10,"completionDate":"2026-09"},{"nctId":"NCT02230176","phase":"PHASE2","title":"Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-02","conditions":["Pancreatic Neuroendocrine Carcinoma"],"enrollment":84,"completionDate":"2024-04"},{"nctId":"NCT05247905","phase":"PHASE2","title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-02-16","conditions":["Metastatic Pancreatic Neuroendocrine Tumor","Unresectable Pancreatic Neuroendocrine Carcinoma"],"enrollment":31,"completionDate":"2033-10-01"},{"nctId":"NCT05249114","phase":"PHASE1","title":"Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-12-28","conditions":["Neuroendocrine Tumors"],"enrollment":6,"completionDate":"2026-12"},{"nctId":"NCT06389097","phase":"","title":"SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-02-03","conditions":["Prostate Cancer","Advanced Cancer"],"enrollment":80,"completionDate":"2029-08"},{"nctId":"NCT04903899","phase":"PHASE2","title":"177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma","status":"RECRUITING","sponsor":"Jakob Stenman","startDate":"2021-05-19","conditions":["Neuroblastoma Recurrent","Neuroblastoma"],"enrollment":24,"completionDate":"2031-05-20"},{"nctId":"NCT04524442","phase":"PHASE4","title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2021-01-25","conditions":["Gastroenteropancreatic Neuroendocrine Tumors"],"enrollment":42,"completionDate":"2023-11-18"},{"nctId":"NCT02489604","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-12","conditions":["Neuroendocrine Tumors"],"enrollment":70,"completionDate":"2024-01"},{"nctId":"NCT04917484","phase":"PHASE2","title":"Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients","status":"RECRUITING","sponsor":"Tine Gregersen, MD","startDate":"2020-02-01","conditions":["Neuroendocrine Neoplasm"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT06607692","phase":"PHASE2","title":"Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","status":"RECRUITING","sponsor":"Fundación de investigación HM","startDate":"2024-10","conditions":["Solid Tumor Cancer","Medulloblastoma","High Risk Neuroblastoma","High Grade Gliomas","Meningioma","Paraganglioma","Pheochromocytoma","Neuroendocrine Tumours (NET)","Adrenal Tumours"],"enrollment":25,"completionDate":"2029-12"},{"nctId":"NCT02236910","phase":"PHASE2","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2014-07","conditions":["Neuroendocrine Carcinoma"],"enrollment":66,"completionDate":"2025-12"},{"nctId":"NCT02754297","phase":"PHASE2","title":"Personalized PRRT of Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2016-04-12","conditions":["Neuroendocrine Tumors","Carcinoid Tumor","Carcinoma, Neuroendocrine"],"enrollment":275,"completionDate":"2029-04-12"},{"nctId":"NCT04946305","phase":"","title":"A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":["Somatostatin Receptor-positive GEP-NET"],"enrollment":89,"completionDate":"2024-07-08"},{"nctId":"NCT04614766","phase":"PHASE1,PHASE2","title":"A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"David Bushnell","startDate":"2022-09-30","conditions":["Gastro-enteropancreatic Neuroendocrine Tumor","Neuroendocrine Tumors"],"enrollment":0,"completionDate":"2024-04-23"},{"nctId":"NCT01763554","phase":"","title":"Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014","status":"UNKNOWN","sponsor":"AHS Cancer Control Alberta","startDate":"2012-08","conditions":["Neuroendocrine Tumors, NET"],"enrollment":115,"completionDate":"2025-12"},{"nctId":"NCT06121271","phase":"PHASE2","title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2023-12-18","conditions":["Bronchial and Thymic Neuroendocrine Tumour","Paraganglioma/ Phaeochromocytoma","Medullary Thyroid Carcinoma","Those Requiring Repeat Peptide Receptor Radionuclide Therapy"],"enrollment":110,"completionDate":"2027-11-06"},{"nctId":"NCT05884255","phase":"PHASE3","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-06","conditions":["Advanced Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":220,"completionDate":"2030-10"},{"nctId":"NCT04543955","phase":"PHASE2","title":"Telotristat With Lutathera in Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Lowell Anthony, MD","startDate":"2021-09-13","conditions":["Neuroendocrine Tumors"],"enrollment":1,"completionDate":"2022-06-03"},{"nctId":"NCT04385992","phase":"PHASE2","title":"Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2020-03-09","conditions":["Neuroendocrine Tumors"],"enrollment":31,"completionDate":"2023-06-26"},{"nctId":"NCT05894486","phase":"PHASE2","title":"Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2023-06-05","conditions":["Neuroendocrine Tumors"],"enrollment":40,"completionDate":"2026-06-05"},{"nctId":"NCT05816720","phase":"","title":"Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-01","conditions":["Neuroendocrine Tumor"],"enrollment":31,"completionDate":"2022-01-31"},{"nctId":"NCT05513469","phase":"NA","title":"Biomarker Identification of Radionuclide Therapy-induced Radiation Responses","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2023-01-01","conditions":["Neuroendocrine Tumors"],"enrollment":20,"completionDate":"2024-10-01"},{"nctId":"NCT01237457","phase":"PHASE2","title":"177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms","status":"COMPLETED","sponsor":"Ebrahim S Delpassand","startDate":"2010-10-27","conditions":["Neuroendocrine Tumors"],"enrollment":143,"completionDate":"2017-07-25"},{"nctId":"NCT04949282","phase":"","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","status":"RECRUITING","sponsor":"Sociedad Española de Medicina Nuclear e Imagen Molecular","startDate":"2021-05-10","conditions":["Neuroendocrine Tumors","Intestinal Neoplasms","Pancreatic Neoplasms","Stomach Neoplasms","Neuroectodermal Tumors","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms","Neoplasms, Nerve Tissue","Gastrointestinal Neoplasms","Digestive System Neoplasms","Neoplasms by Site","Endocrine Gland Neoplasms","Digestive System Diseases","Gastrointestinal Disease","Intestinal Diseases","Pancreatic Disease","Endocrine System Diseases"],"enrollment":5000,"completionDate":"2035-12-31"},{"nctId":"NCT01842165","phase":"PHASE3","title":"177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2013-05","conditions":["Gastroenteropancreatic Neuroendocrine Tumors"],"enrollment":37,"completionDate":"2022-09-19"},{"nctId":"NCT03590119","phase":"PHASE2,PHASE3","title":"Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases","status":"COMPLETED","sponsor":"Marnix Lam","startDate":"2018-08-01","conditions":["Neuroendocrine Tumors","Liver Metastases"],"enrollment":26,"completionDate":"2022-09-01"},{"nctId":"NCT04525638","phase":"PHASE2","title":"A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours","status":"UNKNOWN","sponsor":"Fundación de investigación HM","startDate":"2020-06-29","conditions":["Neuroendocrine Tumours (NET)","Neuroendocrine Carcinomas (NEC)"],"enrollment":30,"completionDate":"2024-09-30"},{"nctId":"NCT01578239","phase":"PHASE3","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2012-09-06","conditions":["Carcinoid Tumor of the Small Bowel","Neuroendocrine Tumour"],"enrollment":231,"completionDate":"2021-01-18"},{"nctId":"NCT03923257","phase":"PHASE1,PHASE2","title":"Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2020-08-04","conditions":["Neuroendocrine Tumors","Pheochromocytoma","Paraganglioma"],"enrollment":0,"completionDate":"2021-06-03"},{"nctId":"NCT03325816","phase":"PHASE1,PHASE2","title":"Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2017-11-20","conditions":["Small Cell Lung Cancer","Small Cell Lung Cancer Extensive Stage"],"enrollment":9,"completionDate":"2020-08-11"},{"nctId":"NCT04106843","phase":"PHASE2","title":"Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-06-13","conditions":["Locally Advanced Adrenal Gland Pheochromocytoma","Locally Advanced Paraganglioma","Metastatic Adrenal Gland Pheochromocytoma","Metastatic Paraganglioma","Metastatic Parathyroid Gland Carcinoma","Pituitary Gland Carcinoma","Somatostatin Receptor Positive","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","Stage IV Thyroid Gland Medullary Carcinoma AJCC v8","Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8","Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8","Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8","Unresectable Adrenal Gland Pheochromocytoma","Unresectable Paraganglioma"],"enrollment":0,"completionDate":"2020-09-03"},{"nctId":"NCT04039516","phase":"PHASE2","title":"Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy","status":"UNKNOWN","sponsor":"King's College Hospital NHS Trust","startDate":"2020-10","conditions":["Carcinoid Heart Disease","Carcinoid Syndrome","Carcinoid Tumor"],"enrollment":20,"completionDate":"2024-12"},{"nctId":"NCT04029428","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression","status":"UNKNOWN","sponsor":"University of Warmia and Mazury","startDate":"2004-11-02","conditions":["Neuroendocrine Tumors"],"enrollment":150,"completionDate":"2021-01-01"},{"nctId":"NCT02125474","phase":"NA","title":"Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia, Columbia","startDate":"2013-11","conditions":["Neuroendocrine Tumors"],"enrollment":39,"completionDate":"2019-10-01"},{"nctId":"NCT02705313","phase":"","title":"EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx","status":"APPROVED_FOR_MARKETING","sponsor":"Advanced Accelerator Applications","startDate":"","conditions":["Neuroendocrine Tumors"],"enrollment":0,"completionDate":""},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":["Gastro-intestinal Neuroendocrine Tumors"],"enrollment":0,"completionDate":"2016-10"},{"nctId":"NCT01201096","phase":"","title":"Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)","status":"UNKNOWN","sponsor":"University of Jena","startDate":"2010-09","conditions":["Liver","Metastasis","Neuroendocrine Tumors"],"enrollment":50,"completionDate":"2018-09"}],"_emaApprovals":[{"date":"2017-09-26","status":"Authorised","company":"Advanced Accelerator Applications"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous"},"_patentsChecked":true,"crossReferences":{"MMSL":"269294","NDDF":"017456","VANDF":"4041266","RXNORM":"1999335","UMLSCUI":"C3272344","chemblId":"CHEMBL4297545","ChEMBL_ID":"CHEMBL3989924","KEGG_DRUG":"D11033","DRUGBANK_ID":"DB13985","PUBCHEM_CID":"76966897","MESH_SUPPLEMENTAL_RECORD_UI":"C447941"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2018-","companyName":"Aaa Usa Inc","relationship":"Original Developer"},{"period":"2017","companyName":"Advanced Accelerator Applications","relationship":"EMA Licensee"},{"period":"2021","companyName":"FUJIFILM TOYAMA CHEMICAL Co., Ltd.","relationship":"PMDA Licensee"}],"publicationCount":4,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:47.711503+00","atcClassification":{"source":"DrugCentral","atcCode":"V10XX04","allCodes":["V10XX04"]},"biosimilarFilings":[],"originalDeveloper":"Aaa Usa Inc","recentPublications":[{"date":"2026 Feb 25","pmid":"41739362","title":"Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.","journal":"EJNMMI research"},{"date":"2024 Nov 28","pmid":"39607652","title":"Radiation exposure and protection advice after [(177)Lu]Lu-DOTA-TATE therapy in China.","journal":"EJNMMI research"},{"date":"2024 Jan","pmid":"37987917","title":"Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group.","journal":"Advances in therapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Aaa Usa Inc","companyId":"aaa-usa-inc","modality":"Peptide","firstApprovalDate":"2018","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-01-26T00:00:00.000Z","mah":"AAA USA INC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2018-01-26T00:00:00.000Z","mah":"AAA USA INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2018-01-26T00:00:00.000Z","mah":"AAA USA INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2018-01-26T00:00:00.000Z","mah":"AAA USA INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2018-01-26T00:00:00.000Z","mah":"AAA USA INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2018-01-26T00:00:00.000Z","mah":"AAA USA INC","brand_name_local":null,"application_number":null},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2021-06-23T00:00:00.000Z","mah":"FUJIFILM TOYAMA CHEMICAL Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"10596278","territory":"US","patent_type":null,"expiry_date":"2038-07-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10596276","territory":"US","patent_type":null,"expiry_date":"2038-07-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":8,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:26.439421+00:00","fieldsConflicting":12,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}